| Execution period | Till May 5, 2027 |
|---|
NSE filing, NSE: HDFCBANK. Summary written from the filing by ALFA Finder's alert engine.
HDFC Bank Ltd: key numbers
- Share price
- ₹685.30
- Market cap
- ₹10,57,263 Cr
- Revenue (annual)
- ₹3,48,615 Cr
- Net profit (annual)
- ₹76,026 Cr
- P/E (TTM)
- 13.2×Sector 19.7×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 39.39%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from HDFC Bank Ltd
All →HDFC Bank Management Change
HDFC Bank confirmed that Anup Bagchi assumed charge as MD & CEO effective October 27, 2026, succeeding Sashidhar Jagdishan. The filing also lists the bank's updated KMP contact details.
HDFC Bank Debt & Borrowing: ₹483 Cr
HDFC Bank confirmed the payment of ₹483 Crore interest on its debt securities (ISIN INE040A08AC9) for the due date of October 22, 2026.
- Value
- ₹483.0 Cr
HDFC Bank Employee Stock Options
HDFC Bank allotted 91,38,522 equity shares to employees upon ESOP/RSU exercise. Paid-up capital rose to 15,42,77,35,870 shares of ₹1 each.
HDFC Bank Annual General Meeting
HDFC Bank issued a postal ballot to re-appoint Mrs. Lily Vadera as Independent Director for three years. E-voting: October 22 to November 20, 2026.
HDFC Bank Earnings Call Transcript: Key Takeaways
Management focused on a strategic pivot toward customer service efficiency and digital adoption to drive growth while navigating current liquidity constraints.
HDFC Bank Management Change
HDFC Bank announced the re-appointment of Mrs. Lily Vadera as Independent Director and the upcoming cessation of service of Mr. Kaizad Bharucha, Deputy Managing Director.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.